•	•		/		×0						1	
Substitute form 1449A/PTO					Complete if Known			<u> </u>		\leftarrow_{\succ}		
					u/	Application Number	09/525,797		180%	-√₹ 2	-6	
INFORMATION DISCLOSURE						\mathbf{I}	Filing Date	15 March 200	0	-17	<u>~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ </u>	2 /
STATEMENT BY APPLICANT &					First Named Inventor	Omplete if Known 09/525,797 15 March 2000 Athanasius A. Anagnostou 1642 S. Ungar 5218.39B			1/20	200		
			E.		6 9	%	Group Art Unit	1642		•	150	_ 0
(use as ma	any she	ets as n	ecessary) 🔇	MAKO	-00		Examiner Name	S. Ungar				600
Sheet	1		of 1	400			Attorney Docket Number	5218.39B				120
	7 0%- 11	- 1	110 54-15				ATENT DOCUMENTS					
Examiner Cite Initials*						N	ame of Patentee or Applicant of Cited Document	Date of Publication of Cited Document		Pages, Columns, Line Where Relevant Passa		Lines,
	1		Number	Kind Code (If known)			or cited bocdment	MM-DD-YYYY		or Relevant Figures		ures
Cit			4,745,099		(II KIKWII)		camatsu et al.	5/17/88		Appear		
gy N	2		5,635,160				utts, et al.	3/6/97				
<u> </u>	+-		033,100			31	ults, et al.	3/0/8/				
	 			 		\vdash						
	 			 			· · · · · · · · · · · · · · · · · · ·					
	<u> </u>		-									
	<u> </u>			<u> </u>	FORE	IGN	PATENT DOCUMENTS					
Examiner	Cite		Foreign Patent				Name of Patentee or	Date of Publication F		Pages, Columns, Lines,		T
Initials*	No.	Office	Office Number		Kind Co		Applicant of Cited	of Cited Document		Where Releva		
	1	J	1		(If know		Document	MM-DD-YYYY	Pa	Passages or Releva Figures Appear		1
									1	, .He. co. / cb	pour	
								*				
												1
									Ī			
			OTHER	PRIOR	ART -	NO	N PATENT LITERATURE	DOCUMENTS				
Examiner	Cite	Include serial s	name of the author	(in CAPF	TAL LET	TER	S), title of the article (when approprodume-issue number(s), publisher, or	late), title of the item (boo	k, mag	azine, jour	nal,	Г
Initials*	No.								•			
Sey	3						Mitogenic and Positive Ch	emotactic Effect on	Endo	othelial C	elis,	
	4	Can e	et al. gran e.C.	Y C C	omoki	<u>. pp</u>	. 5978-5982 (1990)	That Cunnmous at	- 0	4b - f		
- 1	7	Lewis	Cao, et al., gro-s, e-C-X-C-Chemokine Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice, J. Exp. Med., Vol. 182, 2069 (1995)									
	5	Carlin	Carlini et al., Effect of Recombinant Human Erythropoietin (rHuEPO) on Apoptosis in Endothelial Cells,									
i i	-	J. Am	er. Society Nep	hrology	Vol.	7, N	o. 9. pg. 1559; Abstract A1	548 (1996)	_,,,,,,	ulbilai Oc	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	6	J. Amer. Society Nephrology, Vol. 7, No. 9, pg. 1559; Abstract A1548 (1996) Carlini, et al., Recombinant Human Erythropoietin Stimulates Anglogenesis, Kidney International, Vol.										
		47, pp. 740-745 (1995)									1	
. []	7	Cazzola, M., Erythropoietin: biology and clinical applications, Trends in Experimental and Clinical										
		Medicine, Vol. 3, pp. 344-361 (1993)										
ال	8	Hand, et al., Erythropoietin Enhances Vascular Responsiveness to Norepinephrine in Renal Failure,									i	
- <u>-</u> -Y_	<u>.</u>	Kidney International, Vol. 48, pp. 806-813 (1995)										
80	10	International Search Report for PCT/US97/15966										
0	11	Kuriya	Kumar, et al, Basic Pathology, W. B. Saunders Company, Philadelphia, pg. 194 (1992) Kuriyama et al., Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoietin Therapy in									
1		Predie	alysis Patents. A	\m, J. F	lyperte	n. V	ol. 9. No. 5, pp. 426-431 (*	1996)	vi d ull	панару	""	ŀ
	12	Predialysis Patents, Am. J. Hyperten, Vol. 9, No. 5, pp. 426-431 (1996) Kuwata, et al., Treatment of Metastatic Liver Tumors by Intermittent Repetitive Injection of an										==
		Angiogenesis Inhibitor Using an Implantable Port System in a Rabbit Model, Kobe J. Med. Sci., Vol. 43,										
		No. 2,	pp. 83-98 (199	7)								İ
	13	Livnah, et al., Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor										
	4.4	Complex at 2.8 A, Science, Vol. 273, pp. 464-471 (1996)										
- 1	14	Maier, et al., In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-										
	15	470) and the anti-endoglin antibody TEC-11, Anti-Cancer Drugs, Vol. 8, pp. 238 (1997)										
	13	Markham, et al., Epoetin Alfa, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, Vol. 49, No. 2, pp. 232-254 (1995)								İ		
	16	Nagai, et al., Effects of rHuEpo on Cellular Proliferation and Endothelin-1 Production in Cultured										
		Endot	helial Cells. Ner	phrol Di	al Tran	spl:	ant. Vol. 10. pp. 1814-1819	(1995)	ı, Ç UII	ui eu		
	17	Pluda.	Endothelial Cells, Nephrol Dial Transplant, Vol. 10, pp. 1814-1819 (1995) Pluda, J.M., Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic									
		Strate	Strategies, Seminars in Oncology, Vol. 24, pp. 203 (1997)								1	
	18	Takan	Takano, et al., A Diaminoathraquinone Inhibitor of Angiogenesis, J. Pharmacol, Exp. Ther., Vol. 271,									
		pg. 10:	pg. 1027 (1994)]	
	19	Wright	on, et al., Smal	l Peptic	les as l	Pote	ent Mimetics of the Protein I	Hormone Erythropoi	etin,	Science,		
		Vol. 27	Vol. 273, pp. 458-463 (1996)									
Yamaji et al., Brain capillary endothelial cells express two forms of erythropoietin receptor m European J. Biochem., Vol. 239, pp. 494-500 (1996)							RNA,					
- \ 	24	Zurope Variati	ean J. Blochem	, VOI. 2	ເລສ, pp	. 49	4-500 (1996)			 		
1/	21	Yamaji, et al., Brain Capillary Endothelial Cells Express Two Forms of Erythropoietin Receptor mRNA,								- 1		

Examiner Signature	. , ,		Date Considered			
			Date College Ed	/	72/~	,
	1 / L	4 .		1 171	か う 1/)	1
	78	140/	1	l lau'	0,0	•
*EXAMINER: Initial if ref		174	s in conformance with MDED 600			
EXAMINER: INMALICED	erence conside	IPA Whathar ar nat citation i	is in contaminated with MDED 600			4 - 41 10

not in conformance and not considered. Include copy of this form with next communication to applicant.